GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Principia Biopharma Inc (NAS:PRNB) » Definitions » PB Ratio

Principia Biopharma (Principia Biopharma) PB Ratio : 9.44 (As of May. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Principia Biopharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-11), Principia Biopharma's share price is $100.05. Principia Biopharma's Book Value per Share for the quarter that ended in Jun. 2020 was $10.60. Hence, Principia Biopharma's PB Ratio of today is 9.44.

Warning Sign:

Principia Biopharma Inc stock PB Ratio (=8.98) is close to 3-year high of 8.98

The historical rank and industry rank for Principia Biopharma's PB Ratio or its related term are showing as below:

PRNB' s PB Ratio Range Over the Past 10 Years
Min: 3.45   Med: 4.72   Max: 8.98
Current: 8.98

During the past 4 years, Principia Biopharma's highest PB Ratio was 8.98. The lowest was 3.45. And the median was 4.72.

PRNB's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.5 vs PRNB: 8.98

During the past 12 months, Principia Biopharma's average Book Value Per Share Growth Rate was 49.30% per year.

Back to Basics: PB Ratio


Principia Biopharma PB Ratio Historical Data

The historical data trend for Principia Biopharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Principia Biopharma PB Ratio Chart

Principia Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19
PB Ratio
- - 3.85 5.03

Principia Biopharma Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.66 4.46 5.03 5.92 5.64

Competitive Comparison of Principia Biopharma's PB Ratio

For the Biotechnology subindustry, Principia Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Principia Biopharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Principia Biopharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Principia Biopharma's PB Ratio falls into.



Principia Biopharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Principia Biopharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2020)
=100.05/10.598
=9.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Principia Biopharma  (NAS:PRNB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Principia Biopharma PB Ratio Related Terms

Thank you for viewing the detailed overview of Principia Biopharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Principia Biopharma (Principia Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
220 East Grand Avenue, South San Francisco, CA, USA, 94080
Principia Biopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapies for immunology and oncology. Its proprietary Tailored Covalency platform enables to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities. The company pipeline products include PRN1008 and PRN2246 and PRN1371 under BTK franchise.
Executives
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Stefani Wolff officer: Chief Development Officer C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Daniel J. Becker director C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Martin Babler director, officer: President, CEO C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Dolca Thomas officer: Chief Medical Officer C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alan Colowick director C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
Shao-lee Lin director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
David M Goldstein officer: Chief Scientific Officer C/O PRINCIPIA BIOPHARMA INC. 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080
Roy C. Hardiman officer: Chief Business Officer C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Christopher Y Chai officer: Chief Financial Officer 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

Principia Biopharma (Principia Biopharma) Headlines